VVP
GDRX icon

Venture Visionary Partners’s GoodRx Holdings GDRX Stock Holding History

Venture Visionary Partners’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50
Closed -$296 – 879
2022
Q2 		$296 Buy
+50
New +$557 ﹤0.01% 1674

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCMX
Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

Venture Visionary Partners's GDRX Position: Q3 2022 in Review

Venture Visionary Partners sold out of GoodRx Holdings (GDRX) in Q3 2022, closing a stake of 50 shares — an estimated $296 sold.

Venture Visionary Partners first reported a position in GDRX in Q2 2022 and held it in 1 quarter. The position peaked at $296 in Q2 2022. 180 funds tracked by Wall St. Rank hold GDRX as of Q3 2022.

  • Venture Visionary Partners reported no remaining GoodRx Holdings position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 50 GoodRx Holdings shares in Q3 2022, an estimated $296.
  • Venture Visionary Partners first reported a position in GoodRx Holdings in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's GoodRx Holdings position peaked at $296 in Q2 2022.
  • 180 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.